The effect of osteoporosis drug against bone remodeling around femoral implant after total hip arthroplasty

The effect of osteoporosis drug against bone remodeling around femoral implant after total hip arthroplasty - THA bone remodeling study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020381

Enrollment

Registered

2016-01-04

Start date

2016-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hip osetoarthritis Osteoporosis

Interventions

Oral alfacalcidol + inject denosumab 60mg subcutaneously every six months Oral alfacalcidol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients with osteoarthritis of hip who are undergoing a primary total hip arthroplasty 2)BMD T score <-2.5% 3)patients who obtained informed consent in our study

Exclusion criteria

Exclusion criteria: 1)hypocalcemia 2)hypercalcemia 3)patients who are allergic to the study drug 4)patients who had liver dysfunction or renal dysfunction 5)patients who fractured in surgery 6)patients who has been determined to be inappropriate by Officer

Design outcomes

Primary

Measure	Time frame
% change in bone mineral density in zone 7 based on zones of Gruen et al. at 12 months after cementless total hip arthroplasty in groups treated denosumab therapy compared the control groups.	—

Countries

Japan

Contacts

Public ContactShinichi Miyazaki

Mie University Hospital Orthopaedics

shinmiya@clin.medic.mie-u.ac.jp059-231-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026